LLYEli Lilly and CompanyRunning, no new patients
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Non-Small Cell Lung Cancer · Medullary Thyroid Cancer · Colon Cancer · Any Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 857 (final count)
- Started
- May 2, 2017
- Main results expected
- Feb 14, 2025
- Fully finished
- Feb 2027
- Results posted
- Apr 16, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Maximum Tolerated Dose (MTD)
Measured over: Cycle 1 (cycle length = 28 days)
Phase 1: Recommended Phase 2 Dose (RP2D)
Measured over: Cycle 1 (cycle length = 28 days)
Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment
Measured over: Approximately for up to 7 years 8 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03157128 · record last updated 2026-04-16 · checked 2026-11-09 15:36 UTC